Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free LNAI Stock Alerts

Lunai Bioworks (LNAI) Financials

Lunai Bioworks logo
$2.43 -0.05 (-1.98%)
As of 09:44 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Lunai Bioworks

Annual Income Statements for Lunai Bioworks

This table shows Lunai Bioworks' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -2.37 -1.74 -2.14 -6.31 -18 -11 -27 -113 -40 -88 -178
Consolidated Net Income / (Loss)		 -2.37 -1.74 -2.14 -6.31 -18 -11 -27 -113 -40 -88 -178
Net Income / (Loss) Continuing Operations		 -2.37 -1.74 -2.14 -6.31 -18 -11 -27 -113 -40 -88 -178
Total Pre-Tax Income 		-2.55 -2.20 -2.21 -6.42 -18 -11 -27 -113 -40 -88 -178
Total Operating Income		 -2.43 -2.12 -2.40 -5.33 -11 -12 -23 -116 -39 -82 -189
Total Gross Profit		 -0.30 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.30 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 2.13 2.16 2.40 5.33 11 12 23 116 39 82 189
Selling, General & Admin Expense		 1.64 1.23 0.93 3.90 8.42 7.12 7.56 14 15 25 18
Research & Development Expense		 0.00 0.80 0.06 0.62 2.50 4.69 16 8.37 4.17 2.71 0.54
Depreciation Expense		 0.02 0.03 0.01 0.02 0.07 0.11 0.12 0.12 0.11 0.12 0.13
Impairment Charge		 - - - - - - 0.00 93 19 54 170
Total Other Income / (Expense), net		 -0.12 -0.08 0.19 -1.09 -7.03 0.51 -3.45 2.65 -1.13 -6.79 11
Interest Expense		 0.08 0.00 0.03 0.14 0.00 -0.04 0.38 0.25 0.58 2.31 0.73
Other Income / (Expense), net		 -0.04 -0.07 0.22 -1.00 -7.10 0.42 -3.08 2.90 -0.55 -4.47 12
Basic Earnings per Share		 ($0.64) ($0.36) ($0.17) ($0.29) ($0.48) ($0.25) ($0.57) - ($0.71) ($0.91) ($1.08)
Weighted Average Basic Shares Outstanding		 7.50M 9.53M 12.27M 21.94M 37.55M 46.33M 47.17M 52.53M 56.27M 97.51M 165.06M
Diluted Earnings per Share		 ($0.64) ($0.36) ($0.17) ($0.29) ($0.48) ($0.25) ($0.57) - ($0.71) ($0.91) ($1.08)
Weighted Average Diluted Shares Outstanding		 7.50M 9.53M 12.27M 21.94M 37.55M 46.33M 47.17M 52.53M 56.27M 97.51M 165.06M
Weighted Average Basic & Diluted Shares Outstanding		 7.50M 9.53M 12.27M 21.94M 37.55M 46.33M 47.17M 52.53M - - 231.80M

Quarterly Income Statements for Lunai Bioworks

This table shows Lunai Bioworks' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -9.18 -4.53 -59 -16 -44 -7.25 0.19 -127 2.82 -1.80 -2.57
Consolidated Net Income / (Loss)		 -9.18 -4.53 -59 -16 -44 -7.25 0.19 -127 2.82 -1.80 -2.57
Net Income / (Loss) Continuing Operations		 -9.18 -4.53 -59 -16 -44 -7.25 0.19 -127 2.82 -1.80 -2.57
Total Pre-Tax Income 		-9.18 -4.53 -59 -16 -44 -7.25 0.19 -127 2.82 -1.80 -2.57
Total Operating Income		 -8.88 -4.27 -51 -17 -53 -4.55 -4.16 -127 -3.31 -1.82 -1.48
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.02
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.02
Operating Revenue		 - - - - - - 0.00 - - - 0.02
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cost of Revenue		 - - - - - - 0.00 - - - 0.00
Total Operating Expenses		 8.88 4.27 51 17 53 4.55 4.16 127 3.31 1.82 1.45
Selling, General & Admin Expense		 8.29 3.62 7.65 5.00 5.30 4.35 4.22 4.00 2.41 1.77 1.42
Research & Development Expense		 0.57 0.62 1.09 0.43 0.39 0.16 -0.09 0.08 0.02 0.05 0.02
Depreciation Expense		 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.01 0.01
Impairment Charge		 0.00 0.00 43 12 48 0.00 0.00 123 0.83 0.00 0.00
Total Other Income / (Expense), net		 -0.29 -0.26 -7.61 1.37 9.13 -2.71 4.35 0.19 6.13 0.02 -1.14
Interest Expense		 0.30 0.27 0.30 1.44 0.25 0.10 0.19 0.19 6.45 0.12 1.19
Other Income / (Expense), net		 0.00 0.00 -7.29 2.82 9.38 -2.59 4.54 0.48 13 0.14 0.05
Basic Earnings per Share		 ($0.14) ($0.07) ($0.54) ($0.16) ($2.76) ($0.45) $0.00 ($0.76) $0.13 ($0.08) ($0.10)
Weighted Average Basic Shares Outstanding		 64.48M 65.85M 109.25M 97.51M 16.00M 16.18M 16.23M 165.06M 22.52M 23.48M 24.99M
Diluted Earnings per Share		 ($0.14) ($0.07) ($0.54) ($0.16) ($2.76) ($0.45) $0.00 ($0.76) $0.13 ($0.08) ($0.10)
Weighted Average Diluted Shares Outstanding		 64.48M 65.85M 109.25M 97.51M 16.00M 16.18M 16.39M 165.06M 22.52M 23.48M 24.99M
Weighted Average Basic & Diluted Shares Outstanding		 66.70M 143.67M 147.50M 0.00 158.72M 158.72M 172.12M 231.80M 23.43M 24.19M 36.27M

Annual Cash Flow Statements for Lunai Bioworks

This table details how cash moves in and out of Lunai Bioworks' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Net Change in Cash & Equivalents		 2.99 -0.40 3.92 12 -3.32 -3.59 12 -11 -7.30 -1.65 -0.13
Net Cash From Operating Activities		 -2.03 -1.47 -1.18 -4.34 -8.51 -10 -21 -16 -12 -11 -7.87
Net Cash From Continuing Operating Activities		 -2.03 -1.47 -1.18 -7.48 -8.51 -10 -21 -16 -12 -11 -8.01
Net Income / (Loss) Continuing Operations		 -2.37 -1.74 -2.14 -6.31 -18 -11 -27 -113 -40 -88 -178
Consolidated Net Income / (Loss)		 -2.37 -1.74 -2.14 -6.31 -18 -11 -27 -113 -40 -88 -178
Depreciation Expense		 0.05 0.03 0.01 0.02 0.07 0.11 0.12 0.12 0.11 0.12 0.13
Amortization Expense		 - - - - 0.00 0.33 0.30 0.30 0.35 0.58 0.03
Non-Cash Adjustments To Reconcile Net Income		 0.02 0.00 1.00 0.65 2.16 0.61 4.49 96 23 65 176
Changes in Operating Assets and Liabilities, net		 0.27 0.24 -0.05 1.30 7.27 -0.10 1.20 1.43 4.33 12 -5.80
Net Cash From Investing Activities		 -1.95 1.05 -0.20 -0.58 -0.72 -0.18 -0.05 -0.01 -0.03 -1.26 -0.50
Net Cash From Continuing Investing Activities		 -1.95 1.05 -0.20 -0.58 -0.72 -0.18 -0.05 -0.01 -0.03 -1.26 -0.50
Purchase of Property, Plant & Equipment		 - - 0.00 -0.03 -0.72 -0.18 -0.05 -0.01 -0.03 -0.07 0.00
Purchase of Investments		 - - - - - - - - - 0.00 -0.50
Divestitures		 - - - - - - - - 0.00 0.07 0.00
Other Investing Activities, net		 -1.95 1.05 -0.20 -0.25 - - - - 0.00 -1.26 0.00
Net Cash From Financing Activities		 6.67 0.00 5.51 17 6.02 7.20 33 4.25 4.52 11 8.38
Net Cash From Continuing Financing Activities		 6.67 0.00 5.51 17 6.02 7.20 33 4.25 4.52 11 8.38
Repayment of Debt		 -1.43 - - - 0.00 -0.27 - -0.56 -1.12 -0.87 -0.97
Issuance of Debt		 0.81 0.00 2.00 - 0.00 6.47 27 - 0.00 8.05 6.98
Issuance of Common Equity		 7.38 0.00 3.51 17 - 0.00 5.00 0.00 4.01 3.00 2.38
Other Financing Activities, net		 - - - 0.00 6.02 1.00 0.76 4.81 1.63 0.34 0.00
Cash Interest Paid		 0.08 0.00 0.02 0.14 0.00 0.00 0.09 0.08 0.35 0.02 0.02
Cash Income Taxes Paid		 0.00 0.00 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Lunai Bioworks

This table details how cash moves in and out of Lunai Bioworks' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -1.35 -0.28 0.07 -0.09 0.00 0.09 0.61 -0.83 0.53 -0.13 2.66
Net Cash From Operating Activities		 -2.78 -3.15 -2.63 -2.41 -2.02 -2.56 -1.49 -1.81 -1.35 -1.07 -1.03
Net Cash From Continuing Operating Activities		 -2.81 -3.14 -2.60 -2.41 -2.02 -2.56 -1.49 -1.95 -1.35 -1.07 -1.03
Net Income / (Loss) Continuing Operations		 -9.18 -4.53 -59 -16 -44 -7.25 0.19 -127 2.82 -1.80 -2.57
Consolidated Net Income / (Loss)		 -9.18 -4.53 -59 -16 -44 -7.25 0.19 -127 2.82 -1.80 -2.57
Depreciation Expense		 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.04 0.01 0.02
Amortization Expense		 0.17 0.20 0.13 0.09 0.02 0.01 - - 0.02 0.04 0.02
Non-Cash Adjustments To Reconcile Net Income		 5.56 1.00 45 14 49 1.08 1.30 124 -4.86 0.33 1.19
Changes in Operating Assets and Liabilities, net		 0.61 0.16 12 -0.54 -7.23 3.57 -3.01 0.87 0.63 0.35 0.32
Net Cash From Financing Activities		 2.56 2.85 2.64 2.47 2.03 2.59 3.58 0.18 1.34 0.95 3.70
Net Cash From Continuing Financing Activities		 2.56 2.85 2.64 2.47 2.03 2.59 3.58 0.18 1.34 0.95 3.70
Issuance of Debt		 0.75 2.74 1.87 2.69 0.16 2.51 0.86 3.45 1.62 0.20 0.51
Issuance of Common Equity		 2.00 - 1.00 - 2.10 0.28 - -3.00 0.00 0.75 4.50
Other Financing Activities, net		 -0.19 0.11 -0.22 0.65 -0.22 -0.20 2.73 0.70 -0.27 - -0.30
Effect of Exchange Rate Changes		 -0.08 0.08 0.15 -0.09 -0.01 0.06 -0.02 - -0.01 -0.01 -0.01
Cash Interest Paid		 0.01 - 0.01 0.01 0.00 0.01 0.01 0.01 0.01 - 0.13

Annual Balance Sheets for Lunai Bioworks

This table presents Lunai Bioworks' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 6/30/2015 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
Total Assets		 2.07 0.87 4.52 183 180 178 190 85 58 163 8.23
Total Current Assets		 1.91 0.73 4.20 16 12 8.94 21 9.57 2.57 2.00 1.05
Cash & Equivalents		 0.42 0.02 3.94 16 12 8.70 21 9.17 1.87 0.22 0.09
Short-Term Investments		 - - - - - - - - - 0.00 0.39
Prepaid Expenses		 0.00 0.01 0.03 0.04 0.19 0.24 0.23 0.39 0.69 0.67 0.57
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.03 0.69 0.78 0.72 0.59 0.51 0.48 0.37
Total Noncurrent Assets		 0.17 0.14 0.32 167 167 168 168 74 55 161 6.82
Goodwill		 - - 0.00 12 12 12 12 12 12 159 5.96
Intangible Assets		 0.16 0.14 0.12 155 155 155 155 62 43 0.03 0.01
Other Noncurrent Operating Assets		 0.00 0.00 0.20 0.14 0.14 1.84 1.46 1.23 0.94 1.29 0.84
Total Liabilities & Shareholders' Equity		 2.07 0.87 4.52 183 180 178 190 85 58 163 8.23
Total Liabilities		 1.00 1.51 2.99 24 6.78 12 15 12 12 31 30
Total Current Liabilities		 1.00 1.51 2.99 0.87 1.11 1.33 1.89 6.45 11 30 29
Accounts Payable		 0.88 1.19 0.67 0.81 0.77 0.59 0.32 1.40 5.30 9.45 13
Accrued Expenses		 0.02 0.22 0.23 0.07 0.34 0.47 1.18 1.03 0.72 5.31 5.84
Other Current Liabilities		 - 0.00 0.40 - 0.00 0.27 0.38 2.82 5.00 16 11
Total Noncurrent Liabilities		 0.00 0.00 0.00 23 5.67 10 13 5.56 0.78 0.84 0.67
Long-Term Debt		 0.00 - - - 0.00 5.78 5.78 4.58 0.00 - 0.25
Other Noncurrent Operating Liabilities		 0.00 - 0.00 23 5.67 4.71 7.28 0.99 0.78 0.84 0.42
Total Equity & Noncontrolling Interests		 1.08 -0.64 1.53 159 173 166 175 73 47 132 -21
Total Preferred & Common Equity		 1.08 -0.64 1.53 159 173 166 175 73 47 132 -21
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1.08 -0.64 1.53 159 173 166 175 73 47 132 -21
Common Stock		 25 25 30 193 226 231 266 277 291 465 478
Retained Earnings		 -25 -26 -28 -35 -53 -64 -91 -204 -244 -332 -510
Accumulated Other Comprehensive Income / (Loss)		 0.54 0.56 0.35 0.21 0.10 -0.04 -0.01 -0.03 -0.03 -0.17 11

Quarterly Balance Sheets for Lunai Bioworks

This table presents Lunai Bioworks' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 58 58 178 122 111 118 6.96 6.67 9.86
Total Current Assets		 1.91 2.40 1.22 1.95 1.71 3.67 0.80 0.51 3.73
Cash & Equivalents		 0.52 0.24 0.31 0.22 0.31 0.92 0.62 0.49 3.16
Short-Term Investments		 - - - - - 0.71 0.00 0.00 0.00
Prepaid Expenses		 0.32 1.09 0.91 0.49 1.27 0.94 0.18 0.02 0.58
Plant, Property, & Equipment, net		 0.48 0.50 0.49 0.45 0.42 0.39 0.01 0.01 0.01
Total Noncurrent Assets		 55 55 176 119 109 114 6.15 6.14 6.11
Goodwill		 12 12 164 118 108 113 5.96 5.96 5.96
Intangible Assets		 43 43 11 0.03 0.02 0.02 0.02 0.01 0.00
Other Noncurrent Operating Assets		 0.89 0.83 1.41 1.23 1.19 1.01 0.16 0.16 0.15
Total Liabilities & Shareholders' Equity		 58 58 178 122 111 118 6.96 6.67 9.86
Total Liabilities		 11 14 44 24 29 29 20 20 19
Total Current Liabilities		 10 14 21 23 29 29 20 20 19
Accounts Payable		 5.42 5.58 7.99 11 11 12 12 12 13
Accrued Expenses		 0.80 0.78 3.75 5.36 5.51 5.72 4.87 4.93 4.91
Other Current Liabilities		 3.88 7.40 9.13 6.03 12 11 2.76 2.61 1.57
Total Noncurrent Liabilities		 0.72 0.66 23 0.71 0.67 0.50 0.28 0.33 0.25
Long-Term Debt		 - - - - - - - 0.12 0.12
Other Noncurrent Operating Liabilities		 0.72 0.66 20 0.71 0.67 0.50 0.28 0.21 0.13
Total Equity & Noncontrolling Interests		 47 44 134 98 82 88 -13 -14 -9.55
Total Preferred & Common Equity		 47 44 134 98 82 88 -13 -14 -9.55
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 47 44 134 98 82 88 -13 -14 -9.55
Common Stock		 300 301 450 468 470 471 495 496 503
Retained Earnings		 -253 -258 -317 -377 -384 -384 -508 -509 -512
Accumulated Other Comprehensive Income / (Loss)		 -0.06 -0.03 1.03 6.30 -3.85 0.78 -0.13 -0.14 -0.16

Annual Metrics And Ratios for Lunai Bioworks

This table displays calculated financial ratios and metrics derived from Lunai Bioworks' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2014 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025
DEI Shares Outstanding		 9,074,790.00 9,533,290.00 12,433,290.00 36,163,924.00 38,789,310.00 46,497,409.00 47,795,952.00 52,949,967.00 58,283,591.00 442,514,832.00 172,118,569.00
DEI Adjusted Shares Outstanding		 9,074,790.00 9,533,290.00 12,433,290.00 36,163,924.00 38,789,310.00 46,497,409.00 47,795,952.00 52,949,967.00 58,283,591.00 442,514,832.00 172,118,569.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.26 -0.18 -0.17 -0.17 -0.46 -0.25 -0.56 -2.14 -0.68 -0.20 -1.03
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -48.56% 10.57% -899.25% 27.23% -185.66% 38.61% -135.60% -332.66% 65.73% -121.03% -107.38%
EBIT Growth		 -47.86% 11.10% -892.23% 27.50% -185.96% 36.42% -130.23% -327.39% 65.45% -120.21% -105.88%
NOPAT Growth		 -39.70% 12.69% -718.60% 25.99% -106.22% -8.50% -96.26% -396.03% 66.78% -111.74% -131.46%
Net Income Growth		 -10.41% 26.81% -70.47% -194.56% -185.44% 36.63% -134.08% -324.47% 65.02% -122.82% -101.31%
EPS Growth		 -60.00% 43.75% 158.33% -70.59% -65.52% 47.92% -128.00% 0.00% 0.00% -28.17% -18.68%
Operating Cash Flow Growth		 4.53% 27.62% 60.07% -268.44% -96.10% -22.95% -97.05% 23.67% 25.16% 6.82% 28.23%
Free Cash Flow Firm Growth		 -5.54% 90.97% -4,712.22% -1,345.62% 82.97% 57.10% -17.61% 172.63% -125.74% -5,927.59% 114.77%
Invested Capital Growth		 31.96% -173.73% -58.41% 6,719.29% 12.35% 1.58% -2.19% -56.67% -35.53% 195.24% -116.57%
Revenue Q/Q Growth		 -100.00% 0.57% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 15.20% -98.80% -8.25% -71.53% 18.21% -78.64% -110.06% -183.41% 65.93% 1.53% -172.96%
EBIT Q/Q Growth		 15.55% -100.02% -5.64% -42.15% 33.30% -81.95% -100.28% -181.47% 65.65% 1.55% -172.18%
NOPAT Q/Q Growth		 5.09% -35.55% 2.81% 35.48% 48.10% -6.45% -94.19% -262.14% 66.13% 6.67% -138.74%
Net Income Q/Q Growth		 31.44% -185.02% 63.10% -41.93% 15.16% -85.71% -98.56% -179.67% 62.82% 7.79% -165.66%
EPS Q/Q Growth		 30.43% 16.28% 127.66% -61.11% 20.00% -127.27% -96.55% 0.00% 0.00% 0.00% -125.00%
Operating Cash Flow Q/Q Growth		 54.43% -713.99% -38.17% -34.49% -7.68% -0.25% -109.72% 38.81% 6.28% -1.41% 7.11%
Free Cash Flow Firm Q/Q Growth		 31.91% 82.70% -351.21% -9.62% -14.41% 72.18% -84.42% 167.21% -139.69% -14.38% 356.39%
Invested Capital Q/Q Growth		 0.00% -398.55% 130.73% 13.30% 20.29% -0.99% -2.28% -55.31% -35.49% -1.74% -125.09%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 87.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% -5,069.72% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% -4,959.04% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% -5,133.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% -4,057.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 93.03% 78.95% 291.18% 98.26% 100.00% 100.00% 99.53% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 103.18% 100.11% 303.61% 101.54% 99.59% 99.25% 101.38% 100.22% 101.48% 102.69% 100.41%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1,494.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -1,286.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 704.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -104.00% -789.21% -957.33% -7.88% -10.86% -6.73% -15.68% -91.74% -66.63% -99.09% -321.81%
Cash Return on Invested Capital (CROIC)		 -283.27% 0.00% 0.00% -104.12% -16.70% -6.72% -7.92% 8.12% -4.20% -163.59% 0.00%
Operating Return on Assets (OROA)		 0.00% -149.18% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% -117.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -104.00% -789.21% -1,436.00% -7.88% -10.86% -6.73% -15.68% -91.74% -66.63% -99.09% -321.81%
Return on Equity Simple (ROE_SIMPLE)		 -220.11% 272.24% -139.80% -3.98% -10.41% -6.87% -15.30% -156.20% -85.34% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.70 -1.48 -5.04 -3.73 -7.69 -8.35 -16 -81 -27 -57 -132
NOPAT Margin		 0.00% -3,471.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -41.52% -207.94% -8.13% -20.97% -74.05% -40.40% -116.20% -352.05% -481.80% -2,986.07% -13,047.11%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -58.04% -43.30% 619.57%
Cost of Revenue to Revenue		 0.00% 12.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 2,875.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 1,880.31% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 5,046.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -2.47 -2.20 -8.73 -6.33 -18 -12 -26 -113 -39 -86 -177
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.42 -2.17 -8.67 -6.31 -18 -11 -26 -113 -39 -85 -177
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 15.41 0.76 1.01 1.18 1.36 1.41 0.71 1.96 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 16.77 0.00 26.68 0.00 29.21 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 557.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.73 1.01 1.18 1.39 1.43 0.70 1.96 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 559.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 10.63 0.00 0.00 2.31
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.09 -0.16 3.30 0.00 0.00 0.03 0.03 0.08 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.03 0.03 0.06 0.00 0.00 0.00
Financial Leverage		 -0.71 -0.55 -7.28 -0.15 -0.08 -0.04 -0.05 -0.07 -0.04 -0.01 -0.01
Leverage Ratio		 1.60 6.69 18.07 1.17 1.09 1.05 1.08 1.11 1.20 1.24 1.55
Compound Leverage Factor		 1.65 6.70 12.19 1.18 1.09 1.05 1.09 1.11 1.22 1.27 1.56
Debt to Total Capital		 8.54% -19.25% 157.24% 0.00% 0.00% 3.36% 3.20% 7.37% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 8.54% -19.25% 157.24% 0.00% 0.00% 0.00% 0.00% 1.53% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 3.36% 3.20% 5.84% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 91.46% 119.25% 142.76% 100.00% 100.00% 96.64% 96.80% 92.63% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.04 -0.05 -2.34 0.00 0.00 -0.52 -0.22 -0.05 0.00 0.00 0.00
Net Debt to EBITDA		 0.13 -0.04 3.12 0.00 0.00 0.26 0.57 0.03 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -0.52 -0.22 -0.04 0.00 0.00 0.00
Debt to NOPAT		 -0.06 -0.07 -2.45 0.00 0.00 -0.69 -0.35 -0.07 0.00 0.00 0.00
Net Debt to NOPAT		 0.19 -0.05 4.02 0.00 0.00 0.35 0.91 0.04 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -0.69 -0.35 -0.06 0.00 0.00 0.00
Altman Z-Score		 0.00 -42.14 -5.34 2.75 14.79 9.26 8.53 -2.65 -6.57 0.17 -160.99
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.91 0.49 4.21 18.04 11.25 6.70 11.08 1.48 0.23 0.07 0.04
Quick Ratio		 0.86 0.48 4.18 18.00 11.08 6.52 10.96 1.42 0.17 0.01 0.02
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.88 -0.17 -10 -149 -25 -11 -13 9.30 -2.39 -144 21
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -14,460.90% -1,187.07% -5,670.20% -42,155.61% -305,126.76% -39,546.41% -15,577.78% 0.00%
Free Cash Flow to Firm to Interest Expense		 -22.28 -71.98 -392.59 -1,040.26 -590,089.92 0.00 -33.72 37.07 -4.12 -62.33 29.37
Operating Cash Flow to Interest Expense		 -24.06 -622.80 -134.52 -30.28 -197,845.14 0.00 -54.29 -62.73 -20.29 -4.74 -10.85
Operating Cash Flow Less CapEx to Interest Expense		 -24.06 -622.80 -134.52 -30.49 -214,511.86 0.00 -54.42 -62.75 -20.34 -4.77 -10.85
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.33 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 4,811.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 1,112.74 71,406.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 -66,594.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.76 -0.56 -2.16 143 161 163 160 69 45 132 -22
Invested Capital Turnover		 0.00 0.43 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.18 -1.31 -4.81 145 18 2.54 -3.58 -91 -25 87 -154
Enterprise Value (EV)		 0.00 24 21 104 162 193 223 99 31 258 49
Market Capitalization		 0.00 24 24 120 175 196 238 102 33 258 50
Book Value per Share		 $0.12 ($0.07) $0.37 $4.39 $4.46 $3.58 $3.65 $1.37 $0.80 $0.89 ($0.12)
Tangible Book Value per Share		 $0.10 ($0.08) $0.45 ($0.22) $0.17 ($0.01) $0.17 ($0.01) ($0.13) ($0.19) ($0.16)
Total Capital		 1.18 -0.53 13 159 173 172 180 78 47 132 -21
Total Debt		 0.10 0.10 5.06 0.00 0.00 5.78 5.78 5.78 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 5.78 5.78 4.58 0.00 0.00 0.00
Net Debt		 -0.32 0.08 -9.01 -16 -12 -2.92 -15 -3.39 -1.87 -0.22 -0.48
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.03 0.72 0.18 0.05 0.01 0.03 0.07 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.59 -0.70 -3.13 -0.71 -0.90 -1.09 -1.65 -4.86 -10 -29 -29
Debt-free Net Working Capital (DFNWC)		 1.01 -0.67 12 15 11 7.61 19 4.31 -8.46 -28 -28
Net Working Capital (NWC)		 0.91 -0.78 4.84 15 11 7.61 19 3.11 -8.46 -28 -28
Net Nonoperating Expense (NNE)		 0.67 0.25 1.39 2.58 10 3.07 10 32 13 31 46
Net Nonoperating Obligations (NNO)		 -0.32 0.08 -9.01 -16 -12 -2.92 -15 -3.39 -1.87 -0.22 -0.48
Total Depreciation and Amortization (D&A)		 0.05 0.03 0.04 0.02 0.07 0.44 0.42 0.42 0.46 0.70 0.16
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -1,627.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% -1,573.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% -1,813.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.64) ($0.18) ($0.37) ($0.42) ($0.48) ($0.25) ($0.57) ($2.16) $0.00 $0.00 ($1.08)
Adjusted Weighted Average Basic Shares Outstanding		 7.50M 9.53M 13.73M 36.17M 46.27M 46.64M 52.22M 52.53M 0.00 0.00 165.06M
Adjusted Diluted Earnings per Share		 ($0.64) ($0.18) ($0.37) ($0.42) ($0.48) ($0.25) ($0.57) ($2.16) $0.00 $0.00 ($1.08)
Adjusted Weighted Average Diluted Shares Outstanding		 7.50M 9.53M 27.46M 36.17M 46.27M 46.64M 52.22M 52.53M 0.00 0.00 165.06M
Adjusted Basic & Diluted Earnings per Share		 ($0.64) ($0.18) ($0.37) ($0.42) ($0.48) ($0.25) ($0.57) ($2.16) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 7.50M 9.53M 24.53M 21.94M 37.55M 46.33M 47.17M 52.53M 0.00 0.00 231.80M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.70 -1.48 -5.04 -3.73 -7.69 -8.35 -16 -16 -14 -19 -13
Normalized NOPAT Margin		 0.00% -3,471.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% -5,139.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -29.21 -928.79 -249.22 -44.16 -420,695.91 0.00 -69.76 -451.28 -67.38 -37.20 -244.30
NOPAT to Interest Expense		 -20.11 -628.03 -191.97 -26.04 -178,907.50 0.00 -43.15 -323.98 -46.51 -24.69 -182.28
EBIT Less CapEx to Interest Expense		 -29.21 -928.79 -249.22 -44.37 -437,362.63 0.00 -69.89 -451.30 -67.43 -37.23 -244.30
NOPAT Less CapEx to Interest Expense		 -20.11 -628.03 -191.97 -26.25 -195,574.22 0.00 -43.28 -324.00 -46.56 -24.72 -182.28
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -3.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Lunai Bioworks

This table displays calculated financial ratios and metrics derived from Lunai Bioworks' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 65,698,144.00 66,698,144.00 143,668,372.00 442,514,832.00 442,514,832.00 317,434,684.00 158,717,509.00 172,118,569.00 231,802,470.00 - 24,187,356.00
DEI Adjusted Shares Outstanding		 65,698,144.00 66,698,144.00 143,668,372.00 442,514,832.00 442,514,832.00 317,434,684.00 158,717,509.00 172,118,569.00 231,802,470.00 - 24,187,356.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.14 -0.07 -0.41 -0.04 -0.10 -0.02 0.00 -0.74 0.01 - -0.11
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -22.60% 5.26% -1,325.96% 37.80% -405.30% -75.63% 100.70% -792.05% 121.25% 77.00% -438.21%
EBIT Growth		 -23.55% 2.24% -1,294.91% 37.71% -394.84% -67.12% 100.64% -784.98% 121.09% 76.41% -477.71%
NOPAT Growth		 -23.55% 2.24% -1,164.47% 25.42% -500.38% -6.47% 88.43% -642.03% 91.14% 59.89% 75.16%
Net Income Growth		 -19.16% -1.60% -1,262.89% 32.19% -381.87% -60.13% 100.32% -705.59% 106.38% 75.19% -1,459.26%
EPS Growth		 0.00% 0.00% -575.00% 0.00% -1,871.43% -542.86% 100.00% -375.00% 104.71% 82.22% 0.00%
Operating Cash Flow Growth		 -4.66% 11.40% 20.38% -6.73% 27.40% 18.65% 43.52% 24.97% 33.09% 58.15% 30.97%
Free Cash Flow Firm Growth		 -81.28% -74.02% -221.73% -1,260.21% -666.05% -286.99% 142.56% 165.33% 221.57% 326.28% 129.56%
Invested Capital Growth		 -32.23% -36.90% 93.83% 195.24% 112.26% 89.13% -35.12% -116.57% -113.93% -116.98% -114.47%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 61.86% 53.50% -1,348.16% 75.78% -209.85% 83.84% 105.78% -30,947.54% 107.38% -117.49% 15.08%
EBIT Q/Q Growth		 61.26% 51.94% -1,273.98% 75.65% -207.71% 83.77% 105.29% -33,567.02% 107.33% -118.16% 15.22%
NOPAT Q/Q Growth		 61.26% 51.94% -1,103.28% 66.71% -211.84% 91.48% -30.80% -2,034.37% 96.28% 61.42% 18.98%
Net Income Q/Q Growth		 60.45% 50.64% -1,202.46% 73.33% -181.04% 83.60% 102.61% -67,091.71% 102.22% -163.83% -42.90%
EPS Q/Q Growth		 0.00% 50.00% -671.43% 70.37% -1,625.00% 83.70% 100.00% 0.00% 117.11% -161.54% -25.00%
Operating Cash Flow Q/Q Growth		 -22.80% -13.30% 16.30% 8.35% 16.47% -26.95% 41.89% -21.76% 25.51% 20.60% 4.14%
Free Cash Flow Firm Q/Q Growth		 84.54% 41.89% -551.03% 1.76% 9.97% 53.13% 202.65% 50.81% 67.53% -12.75% 4.14%
Invested Capital Q/Q Growth		 3.57% -6.21% 209.32% -1.74% -25.54% -16.43% 6.11% -125.09% 37.40% -1.86% 9.57%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,618.69%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7,054.05%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6,815.14%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12,278.65%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 103.27% 106.07% 100.55% 110.11% 100.57% 101.63% 50.07% 100.24% 30.41% 106.89% 180.17%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.78%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 66.73%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3.74%
Return on Equity (ROE)		 -70.32% -74.63% -95.64% -99.09% -170.49% -200.85% -60.15% -321.81% -308.01% -366.44% -6.52%
Cash Return on Invested Capital (CROIC)		 -10.83% -4.91% -124.11% -163.59% -194.21% -202.80% -7.52% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2.24%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4.03%
Return on Common Equity (ROCE)		 -70.32% -74.63% -95.64% -99.09% -170.49% -200.85% -60.15% -321.81% -308.01% -366.44% -6.52%
Return on Equity Simple (ROE_SIMPLE)		 -88.05% -94.58% -71.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -6.22 -2.99 -36 -12 -37 -3.18 -4.16 -89 -3.31 -1.28 -1.03
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,937.84%
Net Nonoperating Expense Percent (NNEP)		 -223.64% 197.00% 1,680.38% -358.83% -2,755.28% -2,619.50% 511.67% -10,809.76% 2,041.17% -238.60% -69.51%
Return On Investment Capital (ROIC_SIMPLE)		 -13.30% -6.86% -26.76% -9.07% -37.97% -3.87% -4.70% 416.13% 25.37% 9.50% 10.96%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,786.63%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 76.14%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6,915.30%
Earnings before Interest and Taxes (EBIT)		 -8.88 -4.27 -59 -14 -44 -7.14 0.38 -126 9.27 -1.68 -1.43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.69 -4.04 -59 -14 -44 -7.10 0.41 -126 9.33 -1.63 -1.39
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.57 4.85 2.83 1.96 0.07 1.62 0.98 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 470.65
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5.63 4.87 2.84 1.96 0.07 1.62 0.98 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 325.71
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.31 0.16 35.98 1.11
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.01 -0.01
Financial Leverage		 -0.02 0.01 0.01 -0.01 0.00 0.00 -0.01 -0.01 -0.01 -0.01 -0.06
Leverage Ratio		 1.20 1.25 1.28 1.24 1.24 1.35 1.33 1.55 1.51 1.72 1.62
Compound Leverage Factor		 1.24 1.33 1.29 1.37 1.25 1.37 0.66 1.55 0.46 1.84 2.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.25% 0.30% 0.28% 0.00% 0.00% -0.89% -1.27%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.25% 0.30% 0.28% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.89% -1.27%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 99.75% 99.70% 99.72% 100.00% 100.00% 100.89% 101.27%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.03
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.03
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 7.61 2.10 1.52 1.62 -5.55 -2.61 -3.05 -140.61 -100.88 -110.71 -74.76
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.19 0.17 0.06 0.07 0.08 0.06 0.13 0.04 0.04 0.03 0.19
Quick Ratio		 0.16 0.10 0.02 0.01 0.01 0.01 0.09 0.02 0.03 0.02 0.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 16 22 -101 -99 -89 -42 43 65 108 95 99
Operating Cash Flow to CapEx		 0.00% 0.00% -49,751.02% -10,248.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 52.67 81.34 -332.05 -68.97 -356.79 -422.92 227.53 344.33 16.81 778.85 82.53
Operating Cash Flow to Interest Expense		 -9.28 -11.44 -8.67 -1.68 -8.06 -25.88 -7.88 -9.63 -0.21 -8.82 -0.86
Operating Cash Flow Less CapEx to Interest Expense		 -9.28 -11.44 -8.69 -1.70 -8.06 -25.88 -7.88 -9.63 -0.21 -8.82 -0.86
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 46 43 134 132 98 82 87 -22 -14 -14 -13
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -22 -25 65 87 52 39 -47 -154 -112 -96 -100
Enterprise Value (EV)		 260 211 380 258 7.15 133 85 49 2.31 20 6.82
Market Capitalization		 261 211 381 258 7.13 133 86 50 2.93 21 9.86
Book Value per Share		 $0.80 $0.65 $0.94 $0.89 $0.67 $0.52 $0.56 ($0.12) ($0.06) ($0.58) ($0.40)
Tangible Book Value per Share		 ($0.13) ($0.16) ($0.28) ($0.19) ($0.14) ($0.16) ($0.15) ($0.16) ($0.08) ($0.83) ($0.64)
Total Capital		 47 44 134 132 98 82 89 -21 -13 -13 -9.43
Total Debt		 0.00 0.00 0.00 0.00 0.25 0.25 0.25 0.00 0.00 0.12 0.12
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.12
Net Debt		 -0.52 -0.24 -0.31 -0.22 0.02 -0.07 -1.39 -0.48 -0.62 -0.37 -3.04
Capital Expenditures (CapEx)		 0.00 0.00 0.01 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -8.71 -12 -20 -29 -21 -27 -27 -29 -20 -20 -19
Debt-free Net Working Capital (DFNWC)		 -8.19 -11 -20 -28 -21 -27 -25 -28 -19 -19 -16
Net Working Capital (NWC)		 -8.19 -11 -20 -28 -21 -27 -25 -28 -19 -19 -16
Net Nonoperating Expense (NNE)		 2.96 1.54 23 3.76 6.88 4.07 -4.35 38 -6.13 0.52 1.54
Net Nonoperating Obligations (NNO)		 -0.52 -0.24 -0.31 -0.22 0.02 -0.07 -1.39 -0.48 -0.62 -0.37 -3.04
Total Depreciation and Amortization (D&A)		 0.20 0.23 0.16 0.12 0.06 0.04 0.03 0.03 0.06 0.05 0.04
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -89,319.43%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -74,252.71%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -74,252.71%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 ($0.16) $0.00 ($0.04) $0.00 ($0.76) $0.13 ($0.08) ($0.10)
Adjusted Weighted Average Basic Shares Outstanding		 66.70M 143.67M 0.00 97.51M 0.00 161.83M 162.33M 165.06M 22.52M 23.48M 24.99M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($0.16) $0.00 ($0.04) $0.00 ($0.76) $0.13 ($0.08) ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding		 66.70M 143.67M 0.00 97.51M 0.00 161.83M 163.93M 165.06M 22.52M 23.48M 24.99M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 66.70M 143.67M 0.00 0.00 0.00 158.72M 172.12M 231.80M 23.43M 24.19M 36.27M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.22 -2.99 -6.14 -3.82 -4.01 -3.18 -2.91 -2.88 -1.73 -1.28 -1.03
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,937.84%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -12,278.65%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -29.68 -15.53 -193.12 -9.94 -175.79 -72.16 2.00 -672.43 1.44 -13.85 -1.20
NOPAT to Interest Expense		 -20.78 -10.87 -118.39 -8.33 -149.30 -32.18 -22.06 -472.50 -0.51 -10.50 -0.87
EBIT Less CapEx to Interest Expense		 -29.68 -15.53 -193.14 -9.96 -175.79 -72.16 2.00 -672.43 1.44 -13.85 -1.20
NOPAT Less CapEx to Interest Expense		 -20.78 -10.87 -118.41 -8.35 -149.30 -32.18 -22.06 -472.50 -0.51 -10.50 -0.87
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Lunai Bioworks (NASDAQ:LNAI) shows a highly distressed balance sheet, weak recurring operating performance, and heavy dependence on financing to stay liquid. The most recent quarter, Q3 2026, included modest revenue of just $20.9 thousand, but the company still posted a net loss of $2.6 million and negative operating cash flow of $1.0 million. While cash rose during the quarter, that improvement was driven mainly by financing rather than core business strength.

  • Cash & equivalents increased to $3.16 million in Q3 2026 from $491.6 thousand in Q2 2026, giving the company more short-term liquidity.
  • Q3 2026 operating revenue of $20.9 thousand was the first meaningful revenue reported in the provided recent periods.
  • Q1 2026 and Q3 2025 both showed periods of positive net income, although these results were not consistent and appear tied to one-time items.
  • The company generated net cash inflows from financing in Q3 2026 and Q1 2026, which helped offset operating losses.
  • Long-term debt is relatively small at $120 thousand in the latest quarter.
  • The balance sheet includes a large goodwill balance of $5.96 million, which is material relative to total assets and could become an accounting risk if further impairments occur.
  • The company has continued issuing equity and debt across multiple quarters, indicating it remains reliant on outside capital to fund operations.
  • Quarterly results have been highly volatile, with significant swings in net income due to large non-operating and impairment items.
  • Weighted average shares outstanding have risen over time, which suggests ongoing dilution for existing shareholders.
  • Total liabilities of $19.41 million are nearly double total assets of $9.86 million in Q3 2026, leaving shareholders’ equity at a deeply negative $9.55 million.
  • The current ratio remains extremely weak: $3.73 million in current assets versus $19.28 million in current liabilities, signaling near-term liquidity pressure.
  • Accounts payable alone were $12.68 million in Q3 2026, far exceeding cash on hand.
  • Operating losses remain substantial: Q3 2026 operating loss was $1.48 million, and operating cash flow was negative $1.03 million.
  • Revenue is still negligible relative to expenses, with most quarters showing no revenue at all.
  • Q4 2025 featured a massive $122.8 million impairment charge and a net loss of $126.7 million, underscoring the business’s recent instability.
  • The company’s recent cash improvements were funded largely by equity and debt issuance rather than sustainable operations, which raises dilution and financing-risk concerns.

Bottom line: LNAI’s recent quarters show a company that is still struggling to build a durable operating business. The latest quarter improved liquidity, but the balance sheet remains underwater, losses continue, and the company appears dependent on capital raises to keep operating. For retail investors, this is a high-risk profile with significant dilution and solvency concerns.

08/06/26 06:54 AM ETAI Generated. May Contain Errors.

Lunai Bioworks Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Lunai Bioworks' fiscal year ends in June. Their fiscal year 2025 ended on June 30, 2025.

Lunai Bioworks' net income appears to be on an upward trend, with a most recent value of -$178.01 million in 2025, rising from -$2.37 million in 2015. The previous period was -$88.43 million in 2024. See where experts think Lunai Bioworks is headed by visiting Lunai Bioworks' forecast page.

Lunai Bioworks' total operating income in 2025 was -$188.97 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $188.97 million

Over the last 10 years, Lunai Bioworks' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Lunai Bioworks' total liabilities were at $29.58 million at the end of 2025, a 5.0% decrease from 2024, and a 2,870.7% increase since 2015.

In the past 10 years, Lunai Bioworks' cash and equivalents has ranged from $23.37 thousand in 2016 to $20.66 million in 2021, and is currently $92.70 thousand as of their latest financial filing in 2025.

Over the last 10 years, Lunai Bioworks' book value per share changed from 0.12 in 2015 to -0.12 in 2025, a change of -204.5%.


Related Companies

Financial statements for NASDAQ:LNAI last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-ye...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
He bet half his $9 billion on ONE stock
One of the most successful fund managers of the past 50 years put more than $4.5 billion - over half his fund ...
Stansberry Research | Sponsoredtc pixel
BNZI Is Building an AI Growth Engine
Banzai International (NASDAQ: BNZI) is drawing fresh attention after a Zacks Rank 2 (Buy) upgrade signaled imp...
Huge Alerts | Sponsoredtc pixel
This AI fund sends investors payouts every Thursday
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
Free Stock Pick: The Company First in Line for America’s New Super Fuel
The U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...
Banyan Hill Publishing | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel
Elon's Terrifying Warning: America Is "1,000% Going Bankrupt"
The national debt just crossed $39 trillion, and Elon Musk - former head of the Department of Government Effic...
American Hartford Gold | Sponsoredtc pixel